A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Selinexor
Related studies linked through entity extraction aliases.
Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Karyopharm Expanded Access Program for Selinexor
- Status
- AVAILABLE
- Phase
- N/A
Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1
Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE3
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Second-line Immunotherapy for ES-SCLC
- Status
- RECRUITING
- Phase
- NA
Using Tumor Models to Determine Treatments
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Twice-per-weekSelinexor, 2 Days Melphalan
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Telehealth-based Symptom Management for Veterans Treated With Selinexor
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2